Novanta Inc. (Nasdaq: NOVT), a Boston-based technology partner to medical and industrial original equipment manufacturers, announced Tuesday it has entered into a definitive agreement to acquire Riverpoint Medical from private equity firm Arlington Capital Partners in a deal valued at up to $1.45 billion. The transaction includes $1.2 billion in upfront cash consideration at closing, expected in the third quarter of 2026, and a $250 million milestone payment scheduled for the first quarter of 2027, subject to customary regulatory approvals and closing conditions.